PUBLIC COMPANY
save$TSHATaysha Gene Therapies, Inc.
$TSHA4.3300+5.87%Dallas, TX, USupdated 10d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
- phase3A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
- phase2Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
🐶 Hiring Signal
News
- Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapyAs both Taysha Gene Therapies and Neurogene warm up for an important year of readouts, the Rett syndrome community is hopeful of seeing a therapy that can truly change the disease's path.biospace · 22d ago
- Mikhail, Davis on board with regulatory framework tailored to rare disease therapiesNewly permanent CBER and CDER directors Karim Mikhail and Michael Davis are widely expected to continue the FDA’s efforts toward an adaptive framework for rare disease therapies. If approved by the…biospace · 1mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that